- NEWS AND VIEWS
Engineered antibodies to combat viral threats
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Nature 588, 398-399 (2020)
doi: https://doi.org/10.1038/d41586-020-03196-2
References
Bournazos, S., Corti, D., Virgin, H. W. & Ravetch, J. V. Nature 588, 485–490 (2020).
Nimmerjahn, F. & Ravetch, J. V. Nature Rev. Immunol. 8, 34–47 (2008).
Urquhart, L. Nature Rev. Drug Discov. 19, 228 (2020).
Liu, R., Oldham, R. J., Teal, E., Beers, S. A. & Cragg, M. S. Antibodies 9, 64 (2020).
Shields, R. L. et al. J. Biol. Chem. 276, 6591–6604 (2001).
Beers, S. A., Glennie, M. J. & White, A. L. Blood 127, 1097–1101 (2016).
Chan, K. R., Ong, E. Z., Mok, D. Z. & Ooi, E. E. Expert Rev. Anti-Infect. Ther. 13, 1351–1360 (2015).
Minard-Colin, V. et al. Blood 112, 1205–1213 (2008).
Goncalvez, A. P., Engle, R. E., St. Claire, M., Purcell, R. H. & Lai, C.-J. Proc. Natl Acad. Sci. USA 104, 9422–9427 (2007).
Kerntke, C., Nimmerjahn, F. & Biburger, M. Front. Immunol. 11, 118 (2020).
Competing Interests
M.S.C. acts as a consultant for a number of biotech companies, being retained as a consultant for BioInvent, and has received research funding from BioInvent, GSK, UCB, iTeos and Roche. None of these associations relate to antiviral therapy.